Abstracts tagged "canakinumab and corticosteroids"

Abstract Number: 2865 • ACR/ARHP Annual Meeting 2018
Canakinumab, on a Reduced Dose or a Prolonged Dose Interval without Concomitant Corticosteroids and Methotrexate, Maintains Efficacy in Systemic Juvenile Idiopathic Arthritis Patients in Clinical Remission
Pierre Quartier¹, Ekaterina Alexeeva², Carine Wouters³, Inmaculada Calvo⁴, Tilmann Kallinich⁵, Bo Magnusson⁶, Nico Wulffraat⁷, Xiaoling Wei⁸, Alan Slade⁹, Ken Abrams⁹ and Alberto Martini¹⁰, ¹AP-HP, Institut des Maladies Génétiques (IMAGINE), and Université Paris-Descartes, Necker-Enfants Malades Hospital, Paris, France, ²National Medical Research Center of Children's Health and Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, ³Gasthuisberg University Hospital, Leuven, Belgium, ⁴Hospital Universitario La Fe, Valencia, Spain, ⁵Charité Berlin Campus Virchow, Berlin, Germany, ⁶Karolinska University Hospital, Stockholm, Sweden, ⁷University Medical Center Utrecht, Utrecht, Netherlands, ⁸China Novartis Institutes for Biomedical Research Co., Ltd, Beijing, China, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Universita di Genova Pediatria II, Genova, Italy
Background/Purpose: Treatment with canakinumab (CAN), a selective, human anti-IL-1β monoclonal antibody, has shown sustained therapeutic effect along with corticosteroid dose reduction/discontinuation in patients with systemic…
Abstract Number: 271 • ACR/ARHP Annual Meeting 2013
Baseline Characteristics Of Patients With Active Systemic JIA On Canakinumab Therapy Successfully Discontinuing Corticosteroids: Secondary Analyses From A Pivotal PHASE 3 Study
Hermine Brunner¹, Nicolino Ruperto², Tamás Constantin³, Nico Wulffraat^2,4, Gerd Horneff⁴, Jordi Anton², Reinhard Berner², Fabrizia Corona⁵, Rubén J. Cuttica⁶, Marine Desjonqueres², Michel Fischbach², Maria Alessio², Alice Chieng², Wolfgang Emminger², Elie Haddad⁷, Karine Lheritier⁸, Ken Abrams⁹, Josef Hruska⁸, Daniel J. Lovell⁷ and Alberto Martini², ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology International Trials Organization (PRINTO)-Istituto Gaslini, Genova, Italy, ³Pediatric Rheumatology, University Childrens Hospital, Budapest, Hungary, ⁴PRINTO, Genoa, Italy, ⁵PRINTO-Istituto Gaslini, Genova, Italy, ⁶Hospital de Niños Pedro de Elizalde - University of Buenos Aires, Buenes Aires, Argentina, ⁷Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Interleukin-1β (IL-1β) is a key cytokine in the pathogenesis of systemic juvenile idiopathic arthritis (SJIA). Canakinumab (CAN), a selective fully human anti-IL-1β monoclonal antibody,…